Search for a trial

A Phase 3, Randomized, Double-blind Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) or Placebo in Combination With VELCADE and Dexamethasone for the Treatment of Subjects With Relapsed or Refractory Multiple Myeloma

The primary objective of this study is to determine if there is an improvement in progression-free survival(PFS) when siltuximab is added to VELCADE* (bortezomib) and dexamethasone in subjects with relapsedor refractory multiple myeloma.The…

Evaluation of bone marrow hypoxia with 18F-FAZA PET in patients with relapsing multiple myeloma; a pilot study

This pilot study will evaluate whether tumour hypoxia can be demonstrated in the bone marrow compartment of relapsing MM patients by using the tracer 18F-FAZA. The results will be compared with the results of the FDG-PET scan. In addition in vitro…

Revlimid, Endoxan, Prednisone Evaluation After prior revlimid Treatment (REPEAT):;A phase 1 and phase 2 study of lenalidomide (Revlimid) in combination with cyclophosphamide (endoxan) and prednisone (REP) in relapsed/refractory multiple myeloma

Phase 1Primary objective- To determine the maximum tolerated dose (MTD) and recommended phase 2 dose level (RDL) of lenalidomide administered during 21 days of a 4 week cycle, combined with continuous cyclophosphamide and prednisone. See paragraph…